Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
26 February 2024 |
Main ID: |
EUCTR2016-000807-99-DE |
Date of registration:
|
18/07/2016 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
The purpose of this research study is to determine if the new drug resminostat will be able to delay or prevent worsening of disease in patients with advanced stage mycosis fungoides or Sézary Syndrome that have achieved disease control with previous systemic therapy, recently
|
Scientific title:
|
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study - RESMAIN Study |
Date of first enrolment:
|
07/12/2016 |
Target sample size:
|
201 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000807-99 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: no Cross over: no Other: yes Other trial design description: open label phase to follow the blinded phase, see protocol for details If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Austria
|
Belgium
|
France
|
Germany
|
Greece
|
Italy
|
Japan
|
Netherlands
|
Poland
|
Spain
|
Switzerland
|
United Kingdom
| | | | |
Contacts
|
Name:
|
Julia Lion
|
Address:
|
Heinrich-Hertz-Str. 26
63225
Langen
Germany |
Telephone:
|
4961871231436 |
Email:
|
julia.lion@iconplc.com |
Affiliation:
|
ICON Clinical Research Germany GmbH |
|
Name:
|
Julia Lion
|
Address:
|
Heinrich-Hertz-Str. 26
63225
Langen
Germany |
Telephone:
|
4961871231436 |
Email:
|
julia.lion@iconplc.com |
Affiliation:
|
ICON Clinical Research Germany GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Patients with histologically confirmed MF (Stage IIB IVB) or SS in an ongoing CR, PR or SD after at least one prior systemic therapy according to local standards (including but not limited to a-interferon, bexarotene, extracorporeal photopheresis, chemotherapy) or total skin electron beam irradiation, o the most recent systemic therapy must have been completed as planned or stopped due to unacceptable toxicity 2 12 weeks prior to randomisation, i.e. patients should not be withdrawn from a treatment from which they derive benefit 2.Male or female = 18 years 3.Written informed consent obtained prior to any trial specific procedure 4.Eastern Cooperative Oncology Group (ECOG) status score 0-2 5.Adequate haematological, hepatic and renal function, as demonstrated by: a)haemoglobin = 9.0 g/dl (International System [SI] of Units: 5.6 mmol/L) b)absolute neutrophil count = 1,000/mm3 c)platelets = 75 × 109/L d)alanine aminotransferase and aspartate amino-transferase = 2 times upper limit of normal e)total bilirubin = 2 mg/dL (SI units: 34.2 µmol/L) (unless known Gilbert syndrome) f)serum creatinine = 1.5 mg/dL (SI units: 132 µmol/L) g)prothrombin time International Normalised Ratio = 2.3 6. Women of childbearing potential (not post-menopausal for 1 year and not surgically sterile) and males with partners of childbearing potential must be sexually abstinent (i.e. refraining from heterosexual intercourse) or must use a highly effective contraception (at least one of the following: combined (oral, intravaginal or transdermal) or progestegen-only (oral, injectable or implantable) hormonal contraceptives, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomy of the partner from the time of screening to 30 days (female patients) or 3 months (male patients) after the last dose of trial treatment 7.Adequate recovery from precedent non-haematological toxicities, excluding alopecia, to = National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 8.Able to comply with all the requirements of the protocol
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 100 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 100
Exclusion criteria: 1.Patients with PD 2.Known central nervous system involvement 3.History and current cardiovascular complications, including unstable angina pectoris, uncontrolled hypertension, congestive heart failure (New York Heart Association [NYHA] Class III or IV) related to primary cardiac disease, a condition requiring anti arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to randomisation 4.Baseline corrected QT (QTc) interval > 500 milliseconds, [NOTE: QTcF is relevant] 5.History of additional risk factors for Torsade de Pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome) 6.Use of concomitant medications that are known to prolong the QT/QTc interval 7.Concurrent use of any other specific anti tumour therapy including psoralen photo chemotherapy (PUVA), chemotherapy, immunotherapy, hormonal therapy, radiation therapy, or experimental medications 8.Previous or concurrent cancer that is distinct in primary site or histology from CTCL, except curatively treated squamous-cell carcinoma of the skin stage 0-1 and curatively treated melanoma stage 0-1A with a low risk of recurrence/metastasis as per assessment of the investigator, cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumours (Ta, Tis and T1); any cancer curatively treated > 3 years prior to randomisation will be allowed 9.Current evidence of any uncontrolled clinically significant internal, psychiatric or neurologic disease 10.Altered mental status precluding understanding of the informed consent process and/or completion of the necessary trial procedures 11.Pregnant or breast feeding women 12.History of allergic reactions attributed to compounds of similar chemical or biological composition to the trial drugs 13.Active alcohol and/or drug abuse 14.Any other acute or chronic condition that, in the investigator’s opinion, would limit the patient’s ability to complete or participate in this trial
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy MedDRA version: 22.0
Level: LLT
Classification code 10028508
Term: Mycosis fungoides/Sezary syndrome
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
Intervention(s)
|
Product Name: Resminostat Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Resminostat CAS Number: 864814-88-0 Current Sponsor code: 4SC-201 Other descriptive name: BYK 408740 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Film-coated tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Timepoint(s) of evaluation of this end point: PFS (progression free survival) is defined as the time from date of randomisation to first date that criteria for progressive disease (PD) have been met according to the global response score or death due to any cause in the absence of documented PD.
|
Main Objective: The primary objective is to determine if maintenance treatment with resminostat increases progression free survival (PFS) compared to placebo in patients with advanced stage (Stage IIB-IVB) MF or SS that have achieved disease control (complete response [CR], partial response [PR] or stable disease [SD]) with previous systemic therapy.
|
Primary end point(s): Progression free survival (PFS) is defined as the time from date of randomisation to first date that criteria for PD have been met according to the global response score or death due to any cause in the absence of documented PD.
|
Secondary Objective: Key Secondary Objective •To determine if maintenance treatment with resminostat increases time to symptom (pruritus) worsening (TTSW) compared to placebo.
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: TTSW (pruritus), the key secondary endpoint, is defined as the time from date of randomisation to first date that criteria for symptom (pruritus) worsening have been met.
|
Secondary end point(s): Key Secondary Endpoint •TTSW (pruritus)
Secondary Endpoints •TTP •TTNT •PFS2 •PFS3 •ORR (CR, PR) •DOR •OS •HrQoL oVAS (itching) oFACT-G oSkindex-29 •PK analysis (peripheral blood)
|
Secondary ID(s)
|
2016-000807-99-GB
|
4SC-201-6-2015
|
Source(s) of Monetary Support
|
4SC AG
|
Ethics review
|
Status: Approved
Approval date: 07/12/2016
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|